Viewing Study NCT04732117



Ignite Creation Date: 2024-05-06 @ 3:44 PM
Last Modification Date: 2024-10-26 @ 1:55 PM
Study NCT ID: NCT04732117
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2024-05-23
First Post: 2021-01-28

Brief Title: Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis
Sponsor: Novartis Pharmaceuticals
Organization: Novartis

Study Overview

Official Title: A Randomized Double-blind Placebo Controlled Multicenter Study of Subcutaneous Secukinumab to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Chinese Participants With Active Non-radiographic Axial Spondyloarthritis
Status: ACTIVE_NOT_RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to evaluate efficacy safety and tolerability of secukinumab in Chinese patients with active nr-axSpA Treatment difference of secukinumab 150mg vs placebo in Chinese nr-axSpA patients in terms of ASAS 40 response rate as well as safety profile will be provided by the study
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None